- Global Pharma News & Resources

Nanomedical Diagnostics CTO Brett Goldsmith to Speak in Graphene Show at IDTechEx Conference

Nanomedical Diagnostics CTO Brett Goldsmith to Speak in Graphene Show at IDTechEx Conference Dr. Goldsmith will introduce the company's breakthrough Protect and Expose manufacturing process that advances the industry from artisanal graphene biosensors to commercial-grade sensors capable of machine learning.

PR Newswire

SAN DIEGO, Nov. 12, 2018

SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Existing graphene biosensors are hand-made in academic labs using laborious processes that can't be automated. As a result, each sensor takes months to assemble, and high sensor-to-sensor variability yields unreliable data for end users. Nanomedical Diagnostics' proprietary Protect and Expose manufacturing process eliminates these issues, enabling graphene biosensors to be produced in standard silicon semiconductor foundries. By carefully balancing protection for the delicate single-layer graphene and exposure of the material when needed for modification, graphene biosensors are produced at a speed 1000 times faster than academic lab-created sensors, with greatly enhanced quality and reduced cost. On November 14, Dr. Brett Goldsmith will present a talk titled, "Digital Biosensing By Foundry-Fabricated Graphene Sensors" at the IDTechEx 2018 show that describes fabrication details.

The new Protect and Expose fabrication process raises the state-of-the-art in graphene biosensors in three ways:

  • GAME-CHANGING QUANTITIES: Production 1000 times faster than lab-produced biosensors.
  • COMMERCIAL QUALITY: Biosensors with consistent and predictable electrical properties.
  • MACHINE-LEARNING CAPABILITIES: Sensor circuitry directly linked with cloud data processing.

Using a unique material that's both biocompatible and conductive, commercial graphene biosensors have the distinct ability to connect directly to digital networks, opening the world of biochemistry to the possibilities of instantaneous analysis and machine learning for the first time.

"Graphene biosensors have the ability to revolutionize any field that requires mobile, digital biochemical measurements, including machine-learning integrated diagnostics, personal health monitoring, and field-deployable sample testing," says Nanomedical Diagnostics CTO, Brett Goldsmith. "The missing piece was standardized biosensors that offer consistent electrical properties at feasible prices. Our Protect and Expose process opens the door for commercial graphene biosensors to be used at a large scale in numerous industries."

Nanomedical Diagnostics manufactures Agile R100, a graphene biosensor assay platform for drug discovery that has been commercially available since late 2016. Since its launch, over 1,000 silicon foundry-fabricated biosensor chips have been sold for use with Agile R100.

About Nanomedical Diagnostics

Nanomedical Diagnostics ("Nanomed") is a life science company based in San Diego, CA. As the world's leading manufacturer and developer of next-generation graphene biosensors, Nanomed's mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

SOURCE Nanomedical Diagnostics, Inc.

Editor Details

Last Updated: 12-Nov-2018